Syndax Pharmaceuticals, Inc. (SNDX)
Automate Your Wheel Strategy on SNDX
With Tiblio's Option Bot, you can configure your own wheel strategy including SNDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNDX
- Rev/Share 0.5106
- Book/Share 3.616
- PB 4.2282
- Debt/Equity 0.0
- CurrentRatio 5.8038
- ROIC -0.6297
- MktCap 913824450.0
- FreeCF/Share -3.3463
- PFCF -3.1894
- PE -2.7455
- Debt/Assets 0.0
- DivYield 0
- ROE -1.016
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –
Read More
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Syndax Announces Participation in May Investor Conferences
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m.
Read More
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Director Steve Closter - Chief Commercial Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Strategy Officer Conference Call Participants Jason Zemansky - Bank of America Ellen Horste - TD Cowen Peter Lawson - Barclays Michael Schmidt - Guggenheim David Dai - UBS Yigal Nochomovitz - Citi Kalpit Patel - B. Riley Securities Jeet Mukherjee - BTIG Salim Syed …
Read More
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m.
Read More
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - CEO Steve Closter - CCO Neil Gallagher - President and Head of R&D Keith Goldan - CFO Anjali Ganguli - CSO Conference Call Participants Anupam Rama - JPMorgan Brad Canino - Stifel Peter Lawson - Barclays Chris Shibutani - Goldman Sachs Kelly Shi - Jefferies Michael Schmidt - Guggenheim Yigal Nochomovitz - Citi David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Jason Zemansky - Bank of America Operator Good …
Read More
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $1 per share a year ago.
Read More
Syndax Announces Participation in March Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Read More
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025.
Read More
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Read More
About Syndax Pharmaceuticals, Inc. (SNDX)
- IPO Date 2016-03-02
- Website https://www.syndax.com
- Industry Biotechnology
- CEO Mr. Michael A. Metzger M.B.A.
- Employees 270